[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100476486":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":52,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":26,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":26,"enrollmentInfo":64,"targetDuration":26,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":26,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Loewenstein Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"study","EXPERIMENTAL","treatment with Apixaban",[13],"Drug: Apixaban",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","ACTIVE_COMPARATOR","treatment with Enoxaparin",[19],"Drug: Enoxaparin Sodium",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Apixaban","treatment for 6 to 12 weeks",[9],null,{"type":22,"name":28,"description":24,"armGroupLabels":29,"otherNames":26},"Enoxaparin Sodium",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Amiram Catz, MD PhD","CONTACT","972-9-770-9934","amiramc@clalit.org.il",[37],{"facility":38,"status":39,"city":40,"state":26,"zip":26,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Loewenstein Rehabilitation Hospital","RECRUITING","Raanana","Israel","IL",{"type":44,"coordinates":45},"Point",[46,47],34.87386,32.1836,{"lat":47,"lon":46},[50],{"name":51,"role":33,"phone":26,"phoneExt":26,"email":26},"Sara Lipkin",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","amiram-catz","Head of the spinal department","100476486","prevention-of-thromboembolism-using-apixaban-vs-enoxaparin-following-spinal-cord-injury-100476486",false,"NCT05484557","Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury","Inclusion Criteria:\n\n* spinal cord injury (traumatic of not traumatic), Hebrew speaker.\n\nExclusion Criteria:\n\n* contra-indication for anticoagulant treatment\n* concomitant treatment with any other anticoagulant\n* anticoagulant treatment needed for indications other than VTE prevention following spinal cord injury\n* active clinically significant bleeding\n* any lesion or condition considered a significant risk factor for major bleeding.\n* hepatic disease associated with coagulopathy and clinically relevant bleeding risk\n* pregnancy or breast-feeding\n* heart valve related issues\n* galactose intolerance\n* active cancer\n* patients who require thrombolysis or pulmonary embolectomy\n* patients with renal impairment\n* sensitivity to excipients of the medication\n* anti phospholipid syndrome\n* prosthetic heart valve\n* acute ischemic stroke","ALL","18 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"NA","Currently, Enoxaparin is the usual prophylactic anticoagulant treatment at the acute and sub-acute phases of spinal cord injury (SCI). Patients at the sub-acute phase of SCI (rehabilitation) will be given either Enoxaparin 40 mg\u002Fday (control) or Apixaban 2.5-5 mg twice a day. Apixaban dose will be determined by the treating physician. Treatment will be continued for either 6 or 12 weeks following injury (for AIS grades C-D and A-B respectively).\n\nEndpoints: Venous thromboembolism will be evaluated by D-Dimer test every 2 weeks and an ultrasound doppler at the beginning and the end of the treatment. Bleeding events will be recorded and hematocrit will be monitored every two weeks.",[72,73],"Spinal Cord Injuries","Spinal Diseases","2025-05-06",{"date":76,"type":77},"2025-05-09","ACTUAL",{"date":79,"type":77},"2023-09-06",{"date":81,"type":66},"2026-02",{"name":5,"class":6},1]